Mads Krogsgaard Thomsen, Novo Nordisk Foundation CEO (Hollie Adams/Bloomberg via Getty Images)
Flush with cash, Novo Nordisk Foundation now plans to reinvest some GLP-1 profits into regenerative medicines
The Novo Nordisk Foundation, the majority owner of Novo Nordisk, plans to put more money into regenerative medicines, including stem cells and cell therapies for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.